Elite in Juvenile Idiopathic Arthritis (JIA)

Luciana D. Breda

Chieti, IT 
Clinical Trials:Currently Recruiting for 2 Trials
Elite in Juvenile Idiopathic Arthritis (JIA)
Chieti, IT 
OverviewLocationsClinical Research

Overview

Luciana Breda practices in Chieti, Italy. Ms. Breda is rated as an Elite expert by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). Her top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Pericarditis, Arthritis, and Rheumatic Fever.

Her clinical research consists of co-authoring 105 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 33 articles and participated in 6 clinical trials in the study of Juvenile Idiopathic Arthritis (JIA).

Gender
Female

Locations

Chieti, Italy
Other Locations
Via Dei Vestini, Via, 66100, Italy
Genoa, Italy
Brescia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

105 Total Publications

Reproductive Life Stages and Female Sex-Specific Patterns in Uveitis Activity: Data From the AIDA Network Uveitis Registry.
Reproductive Life Stages and Female Sex-Specific Patterns in Uveitis Activity: Data From the AIDA Network Uveitis Registry.
Journal: American journal of ophthalmology
Published: September 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Breda's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 60 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile